Replies to post #116426 on Biotech Values

[sodrock]

Quote:Teva President and CEO Shlomo Yanai said last week after presenting second-quarter results that he had good reason to believe his company was close to getting approval for its generic version of Lovenox, but he gave no timeline.



A simple question by analysts as to "what good reason" may have been a valuable contribution to doing their job.

Whenever I see a citation like this, you know it is a PR job and nothing more.

Tinker

when was this? It seems investors don't believe them.

[zipjet]

Teva President and CEO Shlomo Yanai said last week after presenting second-quarter results that he had good reason to believe his company was close to getting approval for its generic version of Lovenox, but he gave no timeline.

How can that be? A reliable source has told us that TEVA gave up saying that tL was close to approval.

;-)

ij